These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 8690831)

  • 21. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group.
    Emsley RA; Raniwalla J; Bailey PJ; Jones AM
    Int Clin Psychopharmacol; 2000 May; 15(3):121-31. PubMed ID: 10870870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia.
    Conley RR; Kelly DL; Nelson MW; Richardson CM; Feldman S; Benham R; Steiner P; Yu Y; Khan I; McMullen R; Gale E; Mackowick M; Love RC
    Clin Neuropharmacol; 2005; 28(4):163-8. PubMed ID: 16062094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial.
    McConville B; Carrero L; Sweitzer D; Potter L; Chaney R; Foster K; Sorter M; Friedman L; Browne K
    J Child Adolesc Psychopharmacol; 2003; 13(1):75-82. PubMed ID: 12804128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.
    Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D
    Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
    Potkin SG; Gharabawi GM; Greenspan AJ; Mahmoud R; Kosik-Gonzalez C; Rupnow MF; Bossie CA; Davidson M; Burtea V; Zhu Y; Trivedi JK
    Schizophr Res; 2006 Jul; 85(1-3):254-65. PubMed ID: 16797162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.
    Emsley R; Turner HJ; Schronen J; Botha K; Smit R; Oosthuizen PP
    J Clin Psychiatry; 2004 May; 65(5):696-701. PubMed ID: 15163258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
    Lee KU; Jeon YW; Lee HK; Jun TY
    Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia.
    Sumiyoshi T; Jayathilake K; Meltzer HY
    Schizophr Res; 2003 Jul; 62(1-2):65-72. PubMed ID: 12765745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.
    Casey DE; Sands EE; Heisterberg J; Yang HM
    Psychopharmacology (Berl); 2008 Oct; 200(3):317-31. PubMed ID: 18597078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
    Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
    J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia.
    Kasper S; Brecher M; Fitton L; Jones AM
    Int Clin Psychopharmacol; 2004 Sep; 19(5):281-9. PubMed ID: 15289701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.
    McConville BJ; Arvanitis LA; Thyrum PT; Yeh C; Wilkinson LA; Chaney RO; Foster KD; Sorter MT; Friedman LM; Brown KL; Heubi JE
    J Clin Psychiatry; 2000 Apr; 61(4):252-60. PubMed ID: 10830145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
    Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
    Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636).
    Hamner MB; Arvanitis LA; Miller BG; Link CG; Hong WW
    Psychopharmacol Bull; 1996; 32(1):107-10. PubMed ID: 8927658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study.
    Bellino S; Paradiso E; Bogetto F
    J Clin Psychiatry; 2006 Jul; 67(7):1042-6. PubMed ID: 16889446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population.
    Pan PY; Lee MS; Yeh CB
    BMC Psychiatry; 2015 Jan; 15():1. PubMed ID: 25609320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
    Müller MJ; Wetzel H; Eich FX; Rein W; Puech A; Benkert O;
    J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study.
    Genç Y; Taner E; Candansayar S
    Adv Ther; 2007; 24(1):1-13. PubMed ID: 17526456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.